A5016408304- Brain Metastases and Treatment
- Radiopharmaceutical Chemistry and Applications
- Inflammatory mediators and NSAID effects
- Immunotherapy and Immune Responses
- Glioma Diagnosis and Treatment
- Receptor Mechanisms and Signaling
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Cancer Mechanisms and Therapy
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Cancer, Hypoxia, and Metabolism
- Computational Drug Discovery Methods
- CNS Lymphoma Diagnosis and Treatment
- Nanoplatforms for cancer theranostics
- Retinoids in leukemia and cellular processes
- Eicosanoids and Hypertension Pharmacology
- Synthesis and biological activity
- interferon and immune responses
- Immune Cell Function and Interaction
- Immune cells in cancer
- Ferroptosis and cancer prognosis
- Ubiquitin and proteasome pathways
- Autophagy in Disease and Therapy
- Cerebrospinal fluid and hydrocephalus
University of Florida
2017-2025
Florida College
2023-2024
Medical University of South Carolina
2010-2022
MUSC Hollings Cancer Center
2010-2022
Abstract Background Despite advancements in the successful use of immunotherapy treating a variety solid tumors, applications brain tumors have lagged considerably. This is due, at least part, to lack well-characterized antigens expressed within that can mediate tumor rejection; low mutational burden these limits abundance targetable neoantigens; and immunologically “cold” microenvironment hampers generation sustained productive immunologic responses. The field mRNA-based therapeutics has...
Abstract There are numerous mechanisms by which glioblastoma cells evade immunological detection, underscoring the need for strategic combinatorial treatments to achieve appreciable therapeutic effects. However, developing combination therapies is difficult due dose-limiting toxicities, blood-brain-barrier, and suppressive tumor microenvironment. Glioblastoma notoriously devoid of lymphocytes driven in part a paucity lymphocyte trafficking factors necessary prompt their recruitment...
Background and Objective: Diffuse large B-cell lymphoma (DLBCL), a subtype of non-Hodgkin's lymphoma, is the most common lymphoid malignancy in Western world. Treatment DLBCL has been greatly improved recent years with addition monoclonal antibody Rituximab to gold standard CHOP (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) chemotherapy regimen, but these treatments are often ineffective patients highly aggressive disease or advanced age. While CAR-T cells...
Abstract Purpose: An ongoing challenge in cancer is the management of primary and metastatic brain malignancies. This partly due to restrictions blood-brain barrier their unique microenvironment. These challenges are most evident cancers such as lymphoma melanoma, which typically responsive treatment systemic locations but resistant when established brain. We propose interleukin-1 receptor-associated kinase-4 (IRAK-4) a potential target across these diseases describe activity mechanism oral...
Malignant B-cells express measurable levels of human leukocyte antigen (HLA) class II proteins, but often escape immune recognition by CD4 + T cells. Resveratrol (Resv) has been the focus numerous investigations due to its potential chemopreventive and anti-cancer effects, it never tested in regulation components B-cell tumors. Here, we show for first time that Resv treatment enhances HLA II-mediated detection lymphomas altering presentation tumor induced an up-regulation both classical...
Melanoma represents an ever-increasing problem in the western world as incidence rates continue to climb. Though manageable during early stages, late stage metastatic disease is highly resistant current intervention. We have previously shown that gamma-interferon-inducible lysosomal thiol-reductase (GILT) enhances HLA class II antigen processing and immune detection of human melanoma cells. Here we report GILT expression inhibits a potential target, paired box-3 (PAX-3) protein, melanoma....
Prostate cancer is a deadly disease that in drastic need of new treatment strategies for late stage and metastatic prostate cancer. Immunotherapy has emerged as viable option to fill this void. Clinical trials have been conducted induce tumor clearance through cytotoxic T lymphocyte (CTL) activation, these studies had mixed outcomes with the overlying problem being lack complete immune response sustained killing formation specific memory cells. To overcome this, we outlined activating HLA...
Prostate cancer is the second most diagnosed in men and current treatment of advanced prostate ineffective. Immunotherapy has emerged as a promising option for metastatic but its clinical application still early stages development. In order to treat tumors, new directions must be taken improve immunotherapeutic strategies. These include identification effective tumor antigens (Ags), induction HLA class II pathway Ag processing CD4+ T cell activation, ability cells act like presenting cells....
Melanoma is an aggressive skin cancer that has become increasingly prevalent in western populations. Current treatments such as surgery, chemotherapy, and high-dose radiation have had limited success, often failing to treat late stage, metastatic melanoma. Alternative strategies immunotherapies been successful treating a small percentage of patients with disease, although these date not proven enhance overall survival. Several melanoma antigens (Ags) proposed targets for immunotherapeutics...
Abstract Though the current therapies are effective at clearing an early stage prostate cancer, they often fail to treat late‐stage metastatic disease. We aimed investigate molecular mechanisms underlying anticancer effects of a natural triterpenoid, ganoderic acid DM (GA‐DM), on two human cancer cell lines: androgen‐independent carcinoma (PC‐3), and androgen‐sensitive adenocarcinoma (LNCaP). Cell viability assay showed that GA‐DM was relatively more toxic LNCaP cells than PC‐3 (IC 50 s...
Background: Malignant mesothelioma is a largely incurable disease that refractory to current therapies. CD26 multifunctional cell surface protein involved in autoimmune disease, diabetes, and cancer. It has role T function, extracellular modification, as prognostic factor for cancer, therapeutic target malignant mesothelioma. New treatment strategies are urgently needed pleural (MPM), CD26-targeted therapy represents novel approach. Outline: In this review, the most up-to-date literature...
Prostate cancer poses an ongoing problem in the western world accounting for significant morbidity and mortality male population. Current therapy options are effective treating most prostate patients, but a number of patients progress beyond manageable disease. For these immunotherapy has emerged as real option treatment late-stage metastatic Unfortunately, even successful strategies have only led to four-month increase survival. One issue responsible shortcomings is inability stimulate...
<p>Supplemental Figure 6. CA-4948 inhibition of MAPK and NF-κB signaling in MBM.</p>
<p>Supplemental Figure 1. Myddosome signaling in normal human cerebral cortex.</p>
<p>Supplemental Figure 2. CA-4948 affinity for murine IRAK-4.</p>
<p>Supplemental Figure 2. CA-4948 affinity for murine IRAK-4.</p>
<p>Supplemental Figure 8. (a) Representative IHC for Ki67 proliferative marker (pink pseudocolor) in B16F10 MBM tumors isolated on day 7 of treatment (day 12 study) with vehicle control or CA-4948 (100 mg/kg). GFAP (astrocytes, green pseudocolor), CD45 (red and DAPI nuclear stain (blue included, scale bar = 100μm. (b) Quantitative comparison tissue expression shown panel f between (n=5) (n=5), measured as the % positive cells within total cell population defined by count tumor area....
<p>Supplemental Figure 6. CA-4948 inhibition of MAPK and NF-κB signaling in MBM.</p>
<p>Supplemental Figure 3. Active IRAK-4 expression in intracranial tumors.</p>
<p>Supplemental Figure 3. Active IRAK-4 expression in intracranial tumors.</p>
<div>AbstractPurpose:<p>An ongoing challenge in cancer is the management of primary and metastatic brain malignancies. This partly due to restrictions blood-brain barrier their unique microenvironment. These challenges are most evident cancers such as lymphoma melanoma, which typically responsive treatment systemic locations but resistant when established brain. We propose interleukin-1 receptor-associated kinase-4 (IRAK-4) a potential target across these diseases describe...